144 related articles for article (PubMed ID: 38781079)
1. Reversal or Repletion Treatment Strategies and Outcomes of Patients With Major Bleeding Events Managed in the Emergency Department: Large Real-Life Investigation in the Northwestern Healthcare District of Tuscany.
Conti A; Leorin M; Bogazzi IC; Renzi N; Pepe G; Frosini F; Furesi L; Dalla Tomasina L; Pennati P; Ghiadoni L;
Crit Pathw Cardiol; 2024 Jun; 23(2):58-72. PubMed ID: 38781079
[TBL] [Abstract][Full Text] [Related]
2. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
[TBL] [Abstract][Full Text] [Related]
3. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
4. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
5. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
[TBL] [Abstract][Full Text] [Related]
6. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.
Sutton SS; Magagnoli J; Cummings TH; Dettling T; Lovelace B; Christoph MJ; Hardin JW
J Thromb Thrombolysis; 2023 Jul; 56(1):137-146. PubMed ID: 37219827
[TBL] [Abstract][Full Text] [Related]
7. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
J Am Pharm Assoc (2003); 2024; 64(2):395-401. PubMed ID: 37952844
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
[TBL] [Abstract][Full Text] [Related]
9. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
Le Roux P; Pollack CV; Milan M; Schaefer A
J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
[TBL] [Abstract][Full Text] [Related]
10. Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries.
Cooksey GE; Hamilton LA; McMillen JC; Griffard JH; Rowe AS
Neurocrit Care; 2022 Oct; 37(2):471-478. PubMed ID: 35624388
[TBL] [Abstract][Full Text] [Related]
11. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.
Liu J; Elsamadisi P; Philips E; Bauer KA; Eche IM
Am J Health Syst Pharm; 2022 Aug; 79(16):1323-1329. PubMed ID: 35291008
[TBL] [Abstract][Full Text] [Related]
12. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
Lipari L; Yang S; Milligan B; Blunck J
Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
[TBL] [Abstract][Full Text] [Related]
13. Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
Huisman MV; Fanikos J
Am J Med; 2016 Nov; 129(11S):S89-S96. PubMed ID: 27569673
[TBL] [Abstract][Full Text] [Related]
14. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
[TBL] [Abstract][Full Text] [Related]
15. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.
Majeed A; Meijer K; Larrazabal R; Arnberg F; Luijckx GJ; Roberts RS; Schulman S
Thromb Haemost; 2014 Feb; 111(2):233-9. PubMed ID: 24154891
[TBL] [Abstract][Full Text] [Related]
16. Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).
Hussain SS; Tyroch AH; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):76-81. PubMed ID: 27215215
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines.
Milling TJ; Refaai MA; Sengupta N
Dig Dis Sci; 2021 Nov; 66(11):3698-3714. PubMed ID: 33403486
[TBL] [Abstract][Full Text] [Related]
18. How can we reverse bleeding in patients on direct oral anticoagulants?
Crowther M; Cuker A
Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
[TBL] [Abstract][Full Text] [Related]
19. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis.
White CM; Caroti KS; Bessada Y; Hernandez AV; Baker WL; Dobesh PP; van Haalen H; Rhodes K; Coleman CI
Pharmacotherapy; 2024 May; 44(5):394-408. PubMed ID: 38721837
[TBL] [Abstract][Full Text] [Related]
20. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
